This is a pivotal moment for the food industry. Noting that 12% of the US population has tried the drugs, with 6% actively using them, Harold Schmitz at VC firm The March Group said the Ozempic era is helping to rejuvenate the foodtech space, which is now very much alive. Courtney McHugh, chief commercial officer at Amplifye, a UC Davis spinout with an enzyme that helps the body digest protein more effectively, added: Theres an entire secondary market that can come from any breakthrough technology. This is only the first generation of GLP-1 drugs and therefore the first generation of secondary markets, observed McHugh, who said GLP-1 drugs are driving interest in products that solve for energy levels, nutrient deficiencies, and gut issues. They are also prompting renewed interest in protein quality as well as quantity, she claimed
Thus, we hypothesized that central GHSR drives binge-like alcohol drinking independently of peripheral ghrelin
Neurobiol Dis 132:104570
Questa caratteristica ha reso il farmaco molto popolare non solo tra le persone che cercano di perdere qualche chilo, ma anche tra gli atleti , i sollevatori di pesi e gli ossessionati di body composition
You can add or remove members in the next step.
Oversight: The Compounding Dilemma A central tension in the battle between compounding pharmacies and Big Pharma lies in the trade-off between access and safety is: access versus safety
